402 related articles for article (PubMed ID: 21455238)
1. Managing the challenge of chemically reactive metabolites in drug development.
Park BK; Boobis A; Clarke S; Goldring CE; Jones D; Kenna JG; Lambert C; Laverty HG; Naisbitt DJ; Nelson S; Nicoll-Griffith DA; Obach RS; Routledge P; Smith DA; Tweedie DJ; Vermeulen N; Williams DP; Wilson ID; Baillie TA
Nat Rev Drug Discov; 2011 Apr; 10(4):292-306. PubMed ID: 21455238
[TBL] [Abstract][Full Text] [Related]
2. Drug metabolism and metabolite safety assessment in drug discovery and development.
He C; Wan H
Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):1071-1085. PubMed ID: 30215280
[TBL] [Abstract][Full Text] [Related]
3. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
[TBL] [Abstract][Full Text] [Related]
4. Conventional and novel approaches in generating and characterization of reactive intermediates from drugs/drug candidates.
Orhan H; Vermeulen NP
Curr Drug Metab; 2011 May; 12(4):383-94. PubMed ID: 21395525
[TBL] [Abstract][Full Text] [Related]
5. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS
Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652
[TBL] [Abstract][Full Text] [Related]
6. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.
Emoto C; Murayama N; Rostami-Hodjegan A; Yamazaki H
Curr Drug Metab; 2010 Oct; 11(8):678-85. PubMed ID: 20973757
[TBL] [Abstract][Full Text] [Related]
7. Detecting reactive drug metabolites for reducing the potential for drug toxicity.
Grillo MP
Expert Opin Drug Metab Toxicol; 2015; 11(8):1281-302. PubMed ID: 26005795
[TBL] [Abstract][Full Text] [Related]
8. Designing around Structural Alerts in Drug Discovery.
Kalgutkar AS
J Med Chem; 2020 Jun; 63(12):6276-6302. PubMed ID: 31497963
[TBL] [Abstract][Full Text] [Related]
9. Reactive Metabolites: Current and Emerging Risk and Hazard Assessments.
Thompson RA; Isin EM; Ogese MO; Mettetal JT; Williams DP
Chem Res Toxicol; 2016 Apr; 29(4):505-33. PubMed ID: 26735163
[TBL] [Abstract][Full Text] [Related]
10. Requirements for a lead compound to become a clinical candidate.
Hefti FF
BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S7. PubMed ID: 19091004
[TBL] [Abstract][Full Text] [Related]
11. Practical approaches to resolving reactive metabolite liabilities in early discovery.
Dalvie D; Kalgutkar AS; Chen W
Drug Metab Rev; 2015 Feb; 47(1):56-70. PubMed ID: 25410913
[TBL] [Abstract][Full Text] [Related]
12. Metabolite identification and profiling in drug design: current practice and future directions.
Zhang Z; Zhu M; Tang W
Curr Pharm Des; 2009; 15(19):2220-35. PubMed ID: 19601824
[TBL] [Abstract][Full Text] [Related]
13. Predicting toxicities of reactive metabolite-positive drug candidates.
Kalgutkar AS; Dalvie D
Annu Rev Pharmacol Toxicol; 2015; 55():35-54. PubMed ID: 25292426
[TBL] [Abstract][Full Text] [Related]
14. Effective Application of Metabolite Profiling in Drug Design and Discovery.
Cerny MA; Kalgutkar AS; Obach RS; Sharma R; Spracklin DK; Walker GS
J Med Chem; 2020 Jun; 63(12):6387-6406. PubMed ID: 32097005
[TBL] [Abstract][Full Text] [Related]
15. Chemical metabolite synthesis and profiling: Mimicking in vivo biotransformation reactions.
Chhatrapati Bisen A; Nashik Sanap S; Agrawal S; Biswas A; Sankar Bhatta R
Bioorg Chem; 2023 Oct; 139():106722. PubMed ID: 37453238
[TBL] [Abstract][Full Text] [Related]
16. The international serious adverse events consortium.
Holden AL; Contreras JL; John S; Nelson MR
Nat Rev Drug Discov; 2014 Nov; 13(11):795-6. PubMed ID: 25359365
[TBL] [Abstract][Full Text] [Related]
17. A decade of drug metabolite safety testing: industry and regulatory shared learning.
Luffer-Atlas D; Atrakchi A
Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):897-900. PubMed ID: 28797172
[No Abstract] [Full Text] [Related]
18. Managing the liabilities arising from structural alerts: a safe philosophy for medicinal chemists.
Edwards PJ; Sturino C
Curr Med Chem; 2011; 18(20):3116-35. PubMed ID: 21651480
[TBL] [Abstract][Full Text] [Related]
19. Best practices for metabolite quantification in drug development: updated recommendation from the European Bioanalysis Forum.
Timmerman P; Blech S; White S; Green M; Delatour C; McDougall S; Mannens G; Smeraglia J; Williams S; Young G
Bioanalysis; 2016 Jun; 8(12):1297-305. PubMed ID: 27217058
[TBL] [Abstract][Full Text] [Related]
20. Selection of new chemical entities with decreased potential for adverse drug reactions.
Park KB; Dalton-Brown E; Hirst C; Williams DP
Eur J Pharmacol; 2006 Nov; 549(1-3):1-8. PubMed ID: 16979156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
